NCT00266565View on ClinicalTrials.gov

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2001

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Hypereosinophilic SyndromesEosinophilic GastroenteritisChurg-Strauss SyndromeEosinophilic Esophagitis
Interventions
DRUG

Mepolizumab

10mg/kg (max 750 ml) once a month for 3 months

Trial Locations (1)

45229-3039

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT00266565 - Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome | Biotech Hunter | Biotech Hunter